Spots Global Cancer Trial Database for plexiform neurofibroma
Every month we try and update this database with for plexiform neurofibroma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Clinical Trial of Pirfenidone in Adult Patients With Neurofibromatosis 1 | NCT00754780 | Neurofibromatos... | Pirfenidone | 18 Years - 70 Years | Mayo Clinic | |
| Natural History Study of Patients With Neurofibromatosis Type I | NCT00924196 | Neurofibromatos... Malignant Perip... Plexiform Neuro... Optic Glioma Neurofibroma | 4 Weeks - | National Institutes of Health Clinical Center (CC) | ||
| Phase II Study of Binimetinib in Children and Adults With NF1 Plexiform Neurofibromas | NCT03231306 | Neurofibromatos... Plexiform Neuro... | Binimetinib | 1 Year - | University of Alabama at Birmingham | |
| PET/MRI in CNS and Extra-CNS Tumors of Patients With Neurofibromatosis-1 (NF1) | NCT01800032 | Neurofibromatos... Optic Glioma Plexiform Neuro... | 6 Years - | UNC Lineberger Comprehensive Cancer Center | ||
| Use of RAD001 as Monotherapy in the Treatment of Neurofibromatosis 1 Related Internal Plexiform Neurofibromas | NCT01412892 | Neurofibromatos... Plexiform Neuro... Neurofibromatos... | RAD001: Everoli... | 18 Years - 60 Years | Assistance Publique - Hôpitaux de Paris | |
| Natural History Study of Patients With Neurofibromatosis Type I | NCT00924196 | Neurofibromatos... Malignant Perip... Plexiform Neuro... Optic Glioma Neurofibroma | 4 Weeks - | National Institutes of Health Clinical Center (CC) | ||
| A Study of Avutometinib for People With Solid Tumor Cancers | NCT06104488 | Refractory Canc... CNS Tumors CNS Tumor, Adul... CNS Tumor, Chil... MAP Kinase Fami... NF1 Plexiform Neuro... Low-grade Gliom... Optic Pathway G... Neuroblastoma Primary Brain T... Solid Tumor Solid Tumor, Ad... Solid Carcinoma Central Nervous... | Avutometinib | 3 Years - 30 Years | Memorial Sloan Kettering Cancer Center | |
| Combination Chemotherapy in Treating Patients With Neurofibromatosis and Progressive Plexiform Neurofibromas | NCT00030264 | Neurofibromatos... Precancerous Co... | Methotrexate Vinblastine | - 25 Years | Children's Hospital of Philadelphia | |
| Study to Evaluate the Safety, Tolerability, PK Characteristics and Anti-tumor Activity of FCN-159 in Adult and Pediatric Participants With Neurofibromatosis Type 1 | NCT04954001 | Neurofibromatos... Plexiform Neuro... NF1 | FCN-159 | 2 Years - 70 Years | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | |
| Pirfenidone in Treating Young Patients With Neurofibromatosis Type 1 and Plexiform Neurofibromas | NCT00053937 | Neurofibromatos... Precancerous Co... | pirfenidone | 3 Years - 21 Years | National Cancer Institute (NCI) | |
| Selumetinib for the Prevention of Plexiform Neurofibroma Growth in NF Type 1 | NCT06188741 | Neurofibromatos... Plexiform Neuro... | Selumetinib | 1 Year - 8 Years | University of Alabama at Birmingham | |
| R115777 to Treat Children With Neurofibromatosis Type 1 and Progressive Plexiform Neurofibromas | NCT00021541 | Neurofibroma, P... Neurofibromatos... | tipifarnib placebo | 3 Years - 25 Years | National Institutes of Health Clinical Center (CC) | |
| Study to Evaluate the Safety, Tolerability, PK Characteristics and Anti-tumor Activity of FCN-159 in Adult and Pediatric Participants With Neurofibromatosis Type 1 | NCT04954001 | Neurofibromatos... Plexiform Neuro... NF1 | FCN-159 | 2 Years - 70 Years | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | |
| A Retrospective Study on Epidemiological Characteristics of Chinese NF1 Patients in Real World (PROMISE) | NCT06379230 | Neurofibromatos... Plexiform Neuro... | This study is p... | - | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | |
| Sorafenib to Treat Children and Young Adults With Neurofibromatosis Type 1 and Inoperable Plexiform Neurofibromas | NCT00727233 | Neurofibromatos... Plexiform Neuro... | Nexavar (BAY 43... Toxicity, Pharm... Pharmacodynamic... Radiographic Ev... QOL assessment,... Bony Toxicity | 3 Years - 18 Years | National Institutes of Health Clinical Center (CC) | |
| AZD2171 in Treating Patients With Neurofibromatosis Type 1 and Plexiform Neurofibroma and/or Neurofibroma Near the Spine | NCT00326872 | Neurofibromatos... Plexiform Neuro... Spinal Cord Neu... | Cediranib Malea... | 18 Years - | National Cancer Institute (NCI) | |
| Study to Evaluate the Safety, Tolerability, PK Characteristics and Anti-tumor Activity of FCN-159 in Adult and Pediatric Participants With Neurofibromatosis Type 1 | NCT04954001 | Neurofibromatos... Plexiform Neuro... NF1 | FCN-159 | 2 Years - 70 Years | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | |
| FCN-159 in Adult Patients With Symptomatic, Inoperable Neurofibromatosis Type 1-Related Plexiform Neurofibromas | NCT05913037 | Neurofibromatos... Plexiform Neuro... NF1 | Test group (Gro... Control group (... | 18 Years - 70 Years | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | |
| A Retrospective Study on Epidemiological Characteristics of Chinese NF1 Patients in Real World (PROMISE) | NCT06379230 | Neurofibromatos... Plexiform Neuro... | This study is p... | - | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | |
| MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas | NCT03962543 | Plexiform Neuro... Neurofibromatos... | Mirdametinib (P... | 2 Years - | SpringWorks Therapeutics, Inc. | |
| Whole Body MRI to Identify Atypical Neurofibromas in Patients With NF1 | NCT03820778 | Neurofibromatos... Neurofibroma Atypical Neurof... Atypical Neurof... Plexiform Neuro... Von Recklinghau... | Whole Body MRI | 8 Years - 30 Years | Children's National Research Institute | |
| Use of RAD001 as Monotherapy in the Treatment of Neurofibromatosis 1 Related Internal Plexiform Neurofibromas | NCT01412892 | Neurofibromatos... Plexiform Neuro... Neurofibromatos... | RAD001: Everoli... | 18 Years - 60 Years | Assistance Publique - Hôpitaux de Paris | |
| Intermittent Dosing Of Selumetinib In Childhood NF1 Associated Tumours | NCT03326388 | Neurofibromatos... Plexiform Neuro... Optic Nerve Gli... | Selumetinib | 3 Years - 18 Years | Great Ormond Street Hospital for Children NHS Foundation Trust | |
| Phase II Study of Binimetinib in Children and Adults With NF1 Plexiform Neurofibromas | NCT03231306 | Neurofibromatos... Plexiform Neuro... | Binimetinib | 1 Year - | University of Alabama at Birmingham | |
| Sorafenib to Treat Children and Young Adults With Neurofibromatosis Type 1 and Inoperable Plexiform Neurofibromas | NCT00727233 | Neurofibromatos... Plexiform Neuro... | Nexavar (BAY 43... Toxicity, Pharm... Pharmacodynamic... Radiographic Ev... QOL assessment,... Bony Toxicity | 3 Years - 18 Years | National Institutes of Health Clinical Center (CC) | |
| MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas | NCT03962543 | Plexiform Neuro... Neurofibromatos... | Mirdametinib (P... | 2 Years - | SpringWorks Therapeutics, Inc. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
